腎上腺受體和高血壓
Spoorthy Kulkarni1, Ian B Wilkinson2
1Department of Experimental Medicine and Immunotherapeutics, Vascular Research Clinic, ACCI Level 3, Addenbrooke's Hospital, University of Cambridge, Cambridge, UK.
Handbook of experimental pharmacology
|June 18, 2024
概括
高血压是一种常见的疾病,涉及血管变化和末端器官损伤. 早期阶段显示出血动力学变化和脏问题,上腺受体刺激和氨酸-血管氨酸-氨系统发挥关键作用.
科学领域:
- 心血管医学 心血管医学
- 腎臟病學 (nephrology) 是一種醫學專業.
- 药理学 药理学是指药理学的学科.
背景情况:
- 高血压是一种普遍的疾病,由于血管和末端器官损伤导致显著的死亡率和发病率.
- 早期高血压阶段,特别是在年轻男性中,涉及血液动力学变化,如心脏输出量增加和外周阻力.
- 由于增加再吸收而造成的损伤是基本高血压的最初触发因素.
研究的目的:
- 审查高血压的病理生理机制,重点关注上腺素受体刺激和氨酸- ангиотензин-阿尔多斯特系统.
- 讨论 adrenoceptor 对抗剂和其他抗高血压剂的历史和当前治疗作用.
- 为突出高血压管理在特定复杂的医疗条件.
主要方法:
- 对病理生理机制的审查,包括catecholamine对 adrenoceptors和renin-angiotensin-aldosterone系统的影响.
- 对抗高血压药物的治疗演变进行分析,从早期的上腺受体抑制剂到目前的第一线药物.
- 检查高血压在特定的条件,如怀孕,血红细胞瘤和肺动脉高血压.
主要成果:
- 腺体受体刺激 (α1,β1) 和氨酸- ангиотензин- алдостерон系统的激活有助于内皮功能障碍和持续性高血压.
- 虽然最初使用α1阻断剂,α2激动剂和β阻断剂,但由于结局试验结果,它们不再是第一线药物.
- ангиотензин转化酶抑制剂, ангиотензин受体阻断剂,通道阻断剂, thiazide 类利尿剂现在被认为是第一线疗法.
结论:
- 作为高血压的第二线或第三线治疗方法,腺素受体药物仍然很重要.
- 了解上腺受体的作用对于在各种临床环境中管理高血压至关重要.
- 这篇概述为临床医生和研究人员提供了关于上腺受体在高血压病理生理学和治疗中的见解.
相关概念视频
01:17Antihypertensive Drugs: Action of β1 Blockers
421
β1-receptors are primarily located in the heart and kidneys. In cardiac myocytes, these receptors interact with neurotransmitters released by the sympathetic nervous system during heightened activity or danger. As a result, β1-receptors get activated, initiating a series of biochemical processes. Excessive activation of beta receptors due to chronic stress can abnormally increase heart rate and contractility, resulting in high blood pressure or hypertension. To counteract this,...
421
01:27Adrenergic Receptors (Adrenoceptors): Classification
2.5K
Adrenergic receptors, or adrenoceptors, respond to the autonomic neurotransmitter noradrenaline and other endogenous catecholamine agonists. They are classified into two main families, α and β, based on their pharmacological response and are further subdivided depending on their location, elicited response, and affinity to specific agonists or antagonists.
α-Adrenoceptors
α-Adrenoceptors are classified into two main subtypes: α1 and α2. The α1 adrenoceptors,...
α-Adrenoceptors
α-Adrenoceptors are classified into two main subtypes: α1 and α2. The α1 adrenoceptors,...
2.5K
01:17Hormonal Regulation of Blood Pressure
2.6K
Endocrinal or hormonal intervention in the cardiovascular system is predominantly exerted by the catecholamines - epinephrine and norepinephrine, as well as a slew of hormones that interact with renal function to modulate blood volume.
Epinephrine and Norepinephrine
The adrenal medulla releases epinephrine and norepinephrine, catecholamines that enhance and extend the sympathetic or "fight or flight" physiological response. These hormones escalate heart rate and the force of contraction...
Epinephrine and Norepinephrine
The adrenal medulla releases epinephrine and norepinephrine, catecholamines that enhance and extend the sympathetic or "fight or flight" physiological response. These hormones escalate heart rate and the force of contraction...
2.6K
01:22Adrenergic Antagonists: Pharmacological Actions of ɑ-Receptor Blockers
713
α-Adrenergic antagonists, known as α-blockers, exert their effects by inhibiting α-adrenoceptors, leading to specific physiological actions. α1-blockers and α2-blockers have distinct pharmacological actions and therapeutic applications.
α1-blockers: These drugs inhibit α1-adrenoceptors on smooth muscle cells, resulting in vasodilation. This vasodilation lowers blood pressure, making α1-blockers valuable in treating hypertension. Additionally,...
α1-blockers: These drugs inhibit α1-adrenoceptors on smooth muscle cells, resulting in vasodilation. This vasodilation lowers blood pressure, making α1-blockers valuable in treating hypertension. Additionally,...
713
01:31Adrenergic Receptors: ɑ Subtype
1.5K
Adrenoceptors are classified into α and ꞵ classes based on their potencies to catecholamine agonists. α-adrenoceptors show the following order of catecholamine potency:
Adrenaline ≥ Noradrenaline >> Isoprenaline
α-adrenoceptors are further divided into α1 and α2-adrenoceptors.
α1-Adrenoceptors: These receptors are located postsynaptically on the effector organs and cause constriction of smooth muscle mediated by activation of phospholipase...
Adrenaline ≥ Noradrenaline >> Isoprenaline
α-adrenoceptors are further divided into α1 and α2-adrenoceptors.
α1-Adrenoceptors: These receptors are located postsynaptically on the effector organs and cause constriction of smooth muscle mediated by activation of phospholipase...
1.5K
01:26Adrenergic Receptors: β Subtype
1.6K
β-adrenoceptors have varied sensitivities towards adrenaline, noradrenaline, and isoprenaline. The order of agonist potency is as follows:
Isoprenaline > Adrenaline > Noradrenaline
Neurotransmitter binding to these receptors causes activation of adenylyl cyclase resulting in increased concentrations of cAMP and modulation of calcium ion channels within the cell. They are further classified into β1, β2, and β3 subtypes.
β1-adrenoceptors: β1-adrenoceptors...
Isoprenaline > Adrenaline > Noradrenaline
Neurotransmitter binding to these receptors causes activation of adenylyl cyclase resulting in increased concentrations of cAMP and modulation of calcium ion channels within the cell. They are further classified into β1, β2, and β3 subtypes.
β1-adrenoceptors: β1-adrenoceptors...
1.6K